Clinical trials: FDG PET/CT
Multiple Myeloma
Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma
Investigators are doing this study to determine which of four imaging techniques: Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized tomography (CT), 18 FDG PET Magnetic resonance imaging (MRI), C-11 acetate…
- Trial name
- NCT03262389
- Testing
- Fludeoxyglucose PET CT, Sodium Acetate C11 PET CT, Fludeoxyglucose PET MRI
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Michael C Roarke, MD
Liver Metastases, Colorectal Carcinoma
An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.
Estimation of the concordance of Tc 99m localization in liver metastases from colorectal carcinoma using SPECT/CT imaging and abdominal FDG (PET)/CT imaging per subject.
- Trial name
- NCT03029988
- Testing
- Tilmanocept (Technetium Tc 99m tilmanocept Injection), SPECT/CT Imaging
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Navidea Biopharmaceuticals
Cancer
FDG Uptake in Vaginal Tampons is Due to Urine
The etiology of FDG uptake in vaginal tampons during PET/CT examinations remains unclear and can potentially impair image interpretation.
- Trial name
- NCT01215318
- Testing
- modified vaginal tampon
- Where
- Switzerland
- Volunteers
- 44 people
- Sponsor
- Irene Burger
Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer
This randomized phase II trial studies how well positron emission tomography (PET)/computed tomography (CT)-guided radiation therapy works compared to standard radiation therapy in treating patients with stage III non-small cell…
- Conditions
- Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7
- Trial name
- NCT01507428
- Testing
- 18F-Fluoromisonidazole, Carboplatin, Computed Tomography
- Where
- 31 sites in United States, Canada
- Volunteers
- 138 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Nonneoplastic Condition
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00822120
- Testing
- bleomycin sulfate, filgrastim, ABVD regimen
- Where
- 423 sites in United States
- Volunteers
- 371 people
- Sponsor
- SWOG Cancer Research Network
Cholecystitis
FDG-PET/CT in the Evaluation of Patients With Suspected Cholecystitis
This is a pilot study to investigate the ability of fluorodeoxyglucose-positron emission tomography (FDG-PET) and Positron emission tomography-computed tomography (PET/CT) as a direct method of detecting infection and/or…
- Trial name
- NCT00590395
- Testing
- 18FDG (an FDA-approved radiopharmaceutical)
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Alan D. Waxman, M.D.
Multiple Myeloma
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
The purpose of this study is to test 89Zr-DFO-daratumumab, a new imaging agent, to demonstrate its safety and ability to take pictures of the myeloma.
- Trial name
- NCT03665155
- Testing
- 89Zr-daratumumab, PET/CT scans, Blood draws
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Squamous Cell Carcinoma
Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell Carcinoma in the Neck: Comparative Study With FDG PET/CT
The investigators propose a longitudinal study evaluating post-treatment changes in patients with squamous cell carcinoma (SCC) of the neck using an innovative optimized diffusion-weighted imaging (DWI) pulse sequence to identify…
- Trial name
- NCT04685798
- Testing
- Diffusion-weighted imaging magnetic resonance imaging, FDG PET/CT
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Washington University School of Medicine
HIV, Inflammation
PET/CT Imaging Companion Study To ACTG A5314
HIV-infected individuals on antiretroviral therapy (ART) are at increased risk for cardiovascular disease (CVD), likely due to chronically increased inflammation.
- Conditions
- HIV, Inflammation, Atherosclerosis
- Trial name
- PET/CTMTX (NCT02312219)
- Testing
- Folic Acid, Low Dose Methotrexate
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Massachusetts General Hospital
Metastatic Melanoma
Imaging FDG Flare in Melanoma
Up to 35 adult patients with metastatic melanoma planning to start pembrolizumab will be enrolled in this study with a target enrollment of 30 evaluable subjects.
- Trial name
- NCT02791594
- Testing
- Pembrolizumab
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Neoplasms, Secondary
Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients
Evaluation of the diagnostic potential of HER2 imaging using zirconium 89 labelled trastuzumab.
- Conditions
- Breast Neoplasms, Secondary, HER2 Positive Carcinoma of Breast
- Trial name
- IJBMNZrT003 (NCT01420146)
- Testing
- Zr89-trastuzumab
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- Jules Bordet Institute
Pulmonary Sarcoidosis
Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis
The purpose of this study is to assess if ACZ885 will improve lung function in association with reduction of tissue inflammation in patients with chronic sarcoidosis.
- Trial name
- NCT02888080
- Testing
- ACZ885
- Where
- 8 sites in United States, Germany and 1 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma, Smoldering Multiple Myeloma
Imaging in MGUS, SMM and MM
Background: Recent studies have shown that the premalignant conditions monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) have a high risk of progressing to multiple myeloma (MM).
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
- Trial name
- NCT01237054
- Testing
- 18-NaF PET, DCE-MRI, 18-FDG PET/CT
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Cancer Institute (NCI)
Psoriasis, Cardiovascular Disease
Vascular Inflammation in Psoriasis-Ustekinumab (VIP-U)
The VIP-U Study is a clinical trial designed to investigate the effect of ustekinumab (Stelara) and placebo on reducing vascular inflammation and cardiometabolic risk biomarkers in patients with moderate to severe psoriasis.
- Trial name
- VIP-U (NCT02187172)
- Testing
- Ustekinumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- University of Pennsylvania
Metastatic Castration-resistant Prostate Cancer
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
This is a master protocol designed to evaluate the safety and efficacy of investigational therapies in participants with metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT04631601
- Testing
- Acapatamab, Enzalutamide, Abiraterone
- Where
- 14 sites in United States, Australia and 4 more
- Volunteers
- 55 people
- Sponsor
- Amgen
Pulmonary Nodule
Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules
RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 (FDG)-PET/CT scan, done before and after steroid therapy may help doctors assess a patient's response to treatment and help plan the best treatment.
- Trial name
- NCT00906503
- Testing
- dexamethasone, PET/Computed Tomography (CT), fludeoxyglucose (18F)
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Multiple Sclerosis, Neuropathic Pain
Transcranial Direct Current Stimulation to Lower Neuropathic Pain in People With Multiple Sclerosis
Transcranial Direct Current Stimulation (tDCS) is a noninvasive brain stimulation technique that utilizes low amplitude direct currents applied via scalp electrodes to apply currents to the brain and modulate the level of…
- Trial name
- NCT03219073
- Testing
- Active tDCS using tDCS device
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Thorsten Rudroff
Pulmonary Hypertension
11C-acetate/18Fluorodeoxyglucose-FDG PET/CT and Cardiac MRI in Pulmonary Hypertension
This study is looking at differences in metabolism and functional imaging between pulmonary hypertension subjects with normal right ventricular function and persistent right ventricular dysfunction.
- Trial name
- NCT01917136
- Testing
- 11C-acetate, [18F]Fluoro-2-deoxy-2-D-glucose, Cardiac MRI
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Pennsylvania
Carcinoma, Squamous Cell
Determine Tumor Response Using Fluorodeoxyglucose (FDG)- Positron Emission Tomography (PET)/Computed Tomography (CT) Before and After Cetuximab in Patients With Head and Neck Cancer
The purpose of this study is to collect data and evaluate how the tumor is broken down in response to standard of care cetuximab treatment by evaluating the FDG-PET/CT scans, toxicity, see how well the FDG-PET/CT scans predict…
- Trial name
- SCCHN (NCT00671437)
- Testing
- FDG-PET/CT, Cetuximab
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Washington University School of Medicine
Psoriasis, Cardiovascular Disease
Vascular Inflammation in Psoriasis - Extension Study
VIP-E is a one-arm, open-label, 40-52 week extension study to continue or cross over subjects of the VIP study (# 814278) to active drug (adalimumab) to determine if there is sustained improvement in vascular inflammation, lipid…
- Trial name
- VIP-E (NCT01866592)
- Testing
- Adalimumab
- Where
- 9 sites in United States
- Volunteers
- 81 people
- Sponsor
- University of Pennsylvania